Corvus Pharmaceuticals (CRVS) financial statements
Net income was -$15M.
Free cash flow was -$33M.
The diluted share count rose 417% over the period (dilution).
Income statement
Fiscal years, from Corvus Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $29M | $46M | $39M | $38M | $32M | $29M | $24M | $17M | $19M | $34M |
| Selling, general and admin | $8M | $10M | $11M | $11M | $12M | $10M | $8M | $7M | $8M | $9M |
| Operating income | -$37M | -$57M | -$49M | -$49M | -$44M | -$39M | -$33M | -$23M | -$28M | -$43M |
| Pre-tax income | -$36M | -$56M | -$47M | -$47M | -$6M | -$43M | -$31M | -$22M | -$59M | -$13M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$36M | -$56M | -$47M | -$47M | -$6M | -$43M | -$41M | -$27M | -$62M | -$15M |
| EPS (diluted) | -$2.36 | -$2.72 | -$1.71 | -$1.59 | -$0.20 | -$1.03 | -$0.89 | -$0.56 | -$1.02 | -$0.53 |
| Diluted shares | 15M | 20M | 28M | 29M | 29M | 42M | 47M | 48M | 61M | 80M |
Balance sheet
Fiscal years, from Corvus Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $135M | $90M | $115M | $78M | $44M | $70M | $42M | $27M | $52M | $57M |
| Receivables | — | — | — | — | — | — | $588,000 | $26,000 | $75,000 | $37,000 |
| Total current assets | $136M | $91M | $116M | $79M | $45M | $71M | $44M | $28M | $54M | $58M |
| Property, plant and equipment | $3M | $3M | $2M | $1M | $906,000 | $451,000 | $353,000 | $236,000 | $151,000 | $220,000 |
| Total assets | $140M | $95M | $118M | $84M | $86M | $109M | $68M | $46M | $69M | $71M |
| Total current liabilities | $6M | $9M | $7M | $10M | $12M | $10M | $11M | $7M | $35M | $9M |
| Total liabilities | $7M | $10M | $8M | $13M | $13M | $12M | $12M | $7M | $36M | $10M |
| Shareholders' equity | $133M | $85M | $110M | $71M | $72M | $97M | $56M | $39M | $33M | $61M |
| Net debt | -$5M | -$45M | -$39M | -$5M | -$16M | -$63M | -$13M | -$13M | -$9M | -$5M |
Cash flow
Fiscal years, from Corvus Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$28M | -$46M | -$41M | -$37M | -$35M | -$37M | -$27M | -$24M | -$25M | -$33M |
| Capital spending | $2M | $266,000 | $355,000 | $25,000 | $76,000 | $5,000 | $269,000 | $34,000 | — | $174,000 |
| Free cash flow | -$30M | -$46M | -$41M | -$37M | -$35M | -$37M | -$27M | -$24M | — | -$33M |
| Stock-based compensation | $4M | $6M | $7M | $7M | $6M | $4M | $3M | $2M | $3M | $5M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CRVS.
Open CRVS in InvestinglyQuestions
How much free cash flow does Corvus Pharmaceuticals generate?
-$33M in fiscal 2025 (operating cash flow minus capital spending).
From Corvus Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.